Literature DB >> 12907264

Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells.

Anurag Singh Rathore1, S E Sobacke, T J Kocot, D R Morgan, R L Dufield, N M Mozier.   

Abstract

Analyses of crude samples from biotechnology processes are often required in order to demonstrate that residual host cell impurities are reduced or eliminated during purification. In later stages of development, as the processes are further developed and finalized, there is a tremendous volume of testing required to confirm the absence of residual host cell proteins (HCP) and DNA. Analytical tests for these components are very challenging since (1). they may be present at levels that span a million-fold range, requiring substantial dilutions; (2). are not a single component, often existing as fragments and a variety of structures; (3). require high sensitivity for final steps in process; and (4). are present in very complex matrices including other impurities, the product, buffers, salts and solvents. Due to the complex matrices and the variety of potential analytes, the methods of analysis are not truly quantitative for all species. Although these limitations are well known, the assays are still very much in demand since they are required for approval of new products. Methods for final products, described elsewhere, focus on approaches to achieve regulatory requirements. The study described herein will describe the technical rationale for measuring the clearance of HCP and DNA in the entire bioprocessing to purification from an Escherichia coli-derived expression system. Three analytical assays, namely, reversed-phase high-performance liquid chromatography (RP-HPLC), enzyme-linked immunosorbent assay (ELISA), and Threshold Total DNA Assay, were utilized to quantify the protein product, HCP and DNA, respectively. Product quantification is often required for yield estimation and is useful since DNA and HCP results are best expressed as a ratio to product for calculation of relative purification factors. The recombinant E. coli were grown to express the protein of interest as insoluble inclusion bodies (IB) within the cells. The IB were isolated by repeated homogenization and centrifugation and the inclusion body slurry (IBS) was solubilized with urea. After refolding the product, the solution was loaded on several commonly used ion exchangers (CM, SP, DEAE, and Q). Product was eluted in a salt gradient mode and fractions were collected and analyzed for product, HCP and DNA. The IBS used for this study contained about 15 mg/ml product, 38 mg/ml HCP and 1.1 mg/ml DNA. Thus, the relative amounts of HCP and DNA in the IBS was excessive, and about 10(3) times greater than typical (because the cells and IB were not processed with the normal number of washing steps during isolation). This was of interest since similar samples may be encountered when working with non-inclusion body systems, such as periplasmic expressions, or in cases where the upstream unit operations under-perform in IB cleaning. The study described herein describes the development of three robust methods that provide the essential process data needed. These findings are of general interest to other projects since applications of similar analytical technology may be used as a tool to develop processes, evaluate clearance of impurities, and produce a suitable product.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907264     DOI: 10.1016/s0731-7085(03)00157-2

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry.

Authors:  Catalin E Doneanu; Alex Xenopoulos; Keith Fadgen; Jim Murphy; St John Skilton; Holly Prentice; Martha Stapels; Weibin Chen
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

Review 2.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies.

Authors:  Sudhir Sahdev; Sunil K Khattar; Kulvinder Singh Saini
Journal:  Mol Cell Biochem       Date:  2007-09-12       Impact factor: 3.396

3.  A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.

Authors:  Matthew T Mazur; Richard S Seipert; David Mahon; Qinwei Zhou; Tun Liu
Journal:  AAPS J       Date:  2012-05-12       Impact factor: 4.009

4.  Quantification of trace-level DNA by real-time whole genome amplification.

Authors:  Min-Jung Kang; Hannah Yu; Sook-Kyung Kim; Sang-Ryoul Park; Inchul Yang
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

5.  Identification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testing.

Authors:  Katrin Bomans; Antje Lang; Veronika Roedl; Lisa Adolf; Kyrillos Kyriosoglou; Katharina Diepold; Gabriele Eberl; Michael Mølhøj; Ulrike Strauss; Christian Schmalz; Rudolf Vogel; Dietmar Reusch; Harald Wegele; Michael Wiedmann; Patrick Bulau
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

6.  Quality Control of Widely Used Therapeutic Recombinant Proteins by a Novel Real-Time PCR Approach.

Authors:  Babak Mamnoon; Taghi Naserpour Farivar; Ahmad Reza Kamyab; Dariush Ilghari; Ali Khamesipour; Mohsen Karimi Arzenani
Journal:  Iran Biomed J       Date:  2015-06-06

7.  Development of a reference standard of Escherichia coli DNA for residual DNA determination in China.

Authors:  Lan Wang; Chunming Rao; Kai Gao; Yonghong Li; Zhihao Fu; Hua Bi; Junzhi Wang
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.